142 related articles for article (PubMed ID: 37770269)
1. Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia.
Barber VS; Peckham N; Duley L; Francis A; Abhishek A; Moss P; Cook JA; Parry HM
BMJ Open; 2023 Sep; 13(9):e077946. PubMed ID: 37770269
[TBL] [Abstract][Full Text] [Related]
2. Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study).
Abhishek A; Boyton RJ; McKnight Á; Coates L; Bluett J; Barber VS; Cureton L; Francis A; Appelbe D; Eldridge L; Julier P; Peckham N; Valdes AM; Rombach I; Altmann DM; Nguyen-Van-Tam J; Williams HC; Cook JA
BMJ Open; 2022 May; 12(5):e062599. PubMed ID: 35504634
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
4. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
Abhishek A; Boyton RJ; Peckham N; McKnight Á; Coates LC; Bluett J; Barber V; Cureton L; Francis A; Appelbe D; Eldridge L; Julier P; Valdes AM; Brooks T; Rombach I; Altmann DM; Nguyen-Van-Tam JS; Williams HC; Cook JA;
Lancet Respir Med; 2022 Sep; 10(9):840-850. PubMed ID: 35772416
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
7. SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.
Halford S; Wan S; Dragoni I; Silvester J; Nazarov B; Anthony D; Anthony S; Ladds E; Norrie J; Dhaliwal K;
Trials; 2021 Aug; 22(1):550. PubMed ID: 34412682
[TBL] [Abstract][Full Text] [Related]
8. Impact of prior SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-19: a multicentre prospective cohort study among UK healthcare workers - the SIREN (Sarscov2 Immunity & REinfection EvaluatioN) study protocol.
Wallace S; Hall V; Charlett A; Kirwan PD; Cole M; Gillson N; Atti A; Timeyin J; Foulkes S; Taylor-Kerr A; Andrews N; Shrotri M; Rokadiya S; Oguti B; Vusirikala A; Islam J; Zambon M; Brooks TJG; Ramsay M; Brown CS; Chand M; Hopkins S
BMJ Open; 2022 Jun; 12(6):e054336. PubMed ID: 35768083
[TBL] [Abstract][Full Text] [Related]
9. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
[TBL] [Abstract][Full Text] [Related]
10. Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.
Abhishek A; Peckham N; Pade C; Gibbons JM; Cureton L; Francis A; Barber V; Williams JAE; Appelbe D; Eldridge L; Julier P; Altmann DM; Bluett J; Brooks T; Coates LC; Rombach I; Semper A; Otter A; Valdes AM; Nguyen-Van-Tam JS; Williams HC; Boyton RJ; McKnight Á; Cook JA;
Lancet Rheumatol; 2024 Feb; 6(2):e92-e104. PubMed ID: 38267107
[TBL] [Abstract][Full Text] [Related]
11. Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
Tomasulo E; Paul S; Mu R; Tian X; Chen J; Pleyer C; Wiestner A; Sun C
Leuk Lymphoma; 2023 Dec; 64(14):2306-2315. PubMed ID: 37732614
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
13. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.
Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS
Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115
[TBL] [Abstract][Full Text] [Related]
14. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
17. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
[TBL] [Abstract][Full Text] [Related]
18. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
20. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
Elife; 2023 Jan; 12():. PubMed ID: 36692910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
